Feed STRO
ST
Sutro Biopharma, Inc. STRO · NASDAQ
$9.51 +4.39% (+$0.40)
Depth
- Market cap
- $157.7M
- Enterprise value
- $114.1M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 3.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -95.5%
- Gross margin
- 97.2%
- Net margin
- -395.2%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.50
- Free float
- 64.9%
Sector
Healthcare
Industry
Biotechnology
CEO
Jane Chung
Employees
128
Headquarters
South San Francisco
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 15% a year over the last 3 years.
- What to watch: Analysts expect revenue to fall by 50% this fiscal year.
- What to watch: It missed profit estimates 5 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $54.3M against $10.8M.
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number